SCHEMBL14174640

SCHEMBL14174640

CN(C)c1ncnc2c1ncn2C1OC(CSCCC(N)C(=O)O)C(O)C1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 13/20 0.77
DNMT3B Q9UBC3 7/20 0.77
DNMT1 P26358 5/20 0.77
CARM1 Q86X55 2/20 0.77
EHMT2 Q96KQ7 2/20 0.77
PRMT1 Q99873 2/20 0.77
TRDMT1 O14717 1/20 0.77
PRMT5 O14744 1/20 0.77
SUV39H1 O43463 1/20 0.77
PRMT3 O60678 1/20 0.77
INMT O95050 1/20 0.77
NSD2 O96028 1/20 0.77
PNMT P11086 1/20 0.77
NNMT P40261 1/20 0.77
HNMT P50135 1/20 0.77
WDR5 P61964 1/20 0.77
KMT2A Q03164 1/20 0.77
SETDB1 Q15047 1/20 0.77
RBBP5 Q15291 1/20 0.77
EZH2 Q15910 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18272513 0.88 DOT1L (0.81) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL18826562 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL12378912 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL10871157 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL13033864 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL13073142 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL17316165 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL14434697 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL21160481 0.87 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
SCHEMBL3515045 0.87 DOT1L (0.83) DOT1LDNMT3BDNMT1CARM1EHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132525-A1 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132525-A1 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid METHYLGENE INC. (CA) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132525-A1 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid DNMT3B, DNMT1, DNMT3L DOT1L 24/4885DNMT3B 1/4885DNMT1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.